At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
News|Articles|September 4, 2026
6 Dermatology Headlines You Missed in August 2026
Author(s)Tim Smith
Fact checked by: Ryan Livingston
A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.
Advertisement
Advertisement
August of 2026 proved to be another eventful month for the field of
Related to this article
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.
Oral bitopertin met all primary and secondary endpoints in the phase 3 APOLLO trial in EPP, cutting PPIX and increasing pain-free time in light.
Yoseph Dalia, MD, discusses diagnosing and treating pseudofolliculitis barbae, its occupational impact, and barriers to care in skin of color.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Advertisement
Advertisement